ABT-888 (Velaparib) and Cyclophosphamide With Versus Without Doxorubicin in Treating Patients With Metastatic or Unresectable SolidTumors or Non-Hodgkin Lymphoma
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
- Metastatic or unresectable disease
- Standard curative or palliative measures do not exist or are no longer effective
- Documented BRCA1 or BRC2 mutation, triple-negative breast cancer (defined as ER-negative, PR-negative, and HER2-negative, or patients who would benefit from a cyclophosphamide-based regimen
Type of study:
Phase I and Phase II
- Phase I – Group I: Patients receive oral ABT-888 twice daily on days 1-4 and cyclophosphamide IV over 60 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- Phase I – Group II: Patients receive oral ABT-888 and cyclophosphamide IV as in group 1. Patients also receive doxorubicin hydrochloride IV over 15 minutes on day 3. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- Phase II: Patients receive ABT-888, cyclophosphamide, and doxorubicin hydrochloride at the maximum tolerated dose determined in phase I.
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08903
Contact: Clinical Trials Office - Cancer Institute of New Jersey 732-235-8675
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.